Trial · NCT04804241
Senicapoc in Alzheimer's Disease
NCT04804241, Phase 2, Recruiting, University of California, Davis
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Senicapoc in Alzheimer's Disease. Trials, record NCT04804241. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04804241
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Senicapoc in Alzheimer's Disease
- NCT number
- NCT04804241
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 55 participants, estimated
- Lead sponsor
- University of California, Davis
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease
- Interventions
- Senicapoc, Placebo Tablet
- First posted
- 2021-03-18
- Last updated
- 2026-08-17
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Subscale (ADAS-Cog 13) score | Baseline, Week 26, Week 52 | ADAS-Cog 13 is a scale used to measure cognitive dysfunction in a number of neural domains. Total scores range from 0-70, with higher scores indicating greater cognitive impairment and a worse outcome. |
| Primary | Change from Baseline to Week 52 in levels of Cerebrospinal fluid (CSF) biomarkers: IL-1β, IL-6, TNF-α, MCP-1, and IL-10 | Baseline, Week 52 | A lumbar puncture will be done and CSF collected at baseline prior to initiating study treatment and at Week 52 at the end of study treatment |
| Primary | Change from Baseline to Week 52 in levels of serum biomarkers: IL-6, TNF-α, MCP-1, and IL-10 and high sensitivity C-Reactive protein | Baseline, Week 52 | Blood draws will be done and serum processed at baseline prior to initiating study treatment and at Week 52 at the end of study treatment |
| Secondary | Change from Screening in the Clinical Dementia Rating (CDR) sum of boxes score | Screening, Week 26, Week 52 | The CDR is a widely used clinical tool for grading the relative severity of dementia with scores that range from 0 (no impairment) to 3 (severe impairment). A higher score indicates greater cognitive impairment and a worse outcome. |
| Secondary | Change from Baseline in the Everyday Cognition (ECog) score | Baseline, Week 26, Week 52 | The ECog is a validated instrument used to assess cognitively mediated functional abilities in older adults. It is comprised of 39 items and a higher total score indicates greater cognitive impairment and a worse outcome. |
| Secondary | Change from Screening in Montreal Cognitive Assessment (MoCA) score | Screening, Week 26, Week 52 | The MoCA is a diagnostic tool used for detecting Mild Cognitive Impairment and early Alzheimer's disease. The scale goes from 0 to 30. A higher score indicates less cognitive impairment and a better outcome. |
| Secondary | Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) memory score | Baseline, Week 52 | The SENAS was devised to be a broad set of psychometrically matched measures with equivalent Spanish and English versions. The composites are z-scores, the more positive the score is, the less cognitive impairment and the better the outcome. |
| Secondary | Change from Baseline to Week 52 in Spanish English Neuropsychological Assessment Scales (SENAS) executive composite score | Baseline, Week 52 | The SENAS was devised to be a broad set of psychometrically matched measures with equivalent Spanish and English versions. The composites are z-scores, the more positive the score is, the less cognitive impairment and the better the outcome. |
| Secondary | Change from Baseline in Bushcke Cued Selective Reminding Task (CSRT) score | Baseline, Week 26, Week 52 | The CSRT is widely used to identify mild dementia and measure associative learning and memory. It involves a study phase where subjects identify pictured items in response to category cures. This is followed by a free recall period and then a cued recall period where category cues are presented to the subjects. The raw score for the CSRT is 0 to 48 (16 items with 3 recall trials). The combined scores when combining the Free plus Cued Recall trials is 0 to 96. The higher the score, the less cognitive impairment and the better the outcome. |
| Secondary | Change from Baseline in Trails B score | Baseline, Week 26, Week 52 | The Trails B is a well-established measure of executive function in which subjects must serially connect alternating numbers and letters. It is scored based on accuracy and time to completion. A longer time to complete indicates greater cognitive impairment and a worse outcome. |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Selective Reminding Task | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04804241
GET https://conductscience.org/api/trials/v1/NCT04804241/registered